Amicus director disposes 113,941 shares in merger
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Amicus Therapeutics director Lynn Dorsey Bleil reported disposing of her equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical Inc. In the transaction, she disposed of 113,941 shares of Common Stock at $14.50 per share and her holdings in this filing fell to zero.
The footnotes state that the disposition occurred upon consummation of the Merger and that each reported stock option was cancelled and converted into a cash payment based on $14.50 per share minus the applicable exercise price, multiplied by the number of option shares. The filing indicates that each option was fully vested or vested in full in connection with the Merger.
Insider Trade Summary
Disposition: 395,940 shares
Disposition
9 txns
Insider
Bleil Lynn Dorsey
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Options (right to buy) | 14,605 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 19,473 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 18,574 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 36,111 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 45,423 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 30,474 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 42,467 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 74,872 | $0.00 | $0.00 |
| Disposition | Common Stock | 113,941 | $14.50 | $1.65M |
Holdings After Transaction:
Stock Options (right to buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (4)
- F1. The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 38,205 shares of Common Stock and 75,736 restricted stock units (which vested in full in connection with consummation of the Merger).
- F2. In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
- F3. Each Option was fully vested.
- F4. Each Option vested in full in connection with consummation of the Merger.
Key Figures
Common Stock disposed: 113,941 shares at $14.50/share
Restricted stock units vested: 75,736 RSUs
Common shares included: 38,205 shares
+5 more
8 metrics
Common Stock disposed
113,941 shares at $14.50/share
Consideration per share in merger-related disposition
Restricted stock units vested
75,736 RSUs
Vested in full upon consummation of the Merger
Common shares included
38,205 shares
Portion of reported securities in merger disposition
Option cancellation block 1
74,872 options at $5.96 exercise price
Cancelled and paid in cash based on $14.50 per share
Option cancellation block 2
42,467 options at $10.27 exercise price
Cancelled for cash upon consummation of the Merger
Option cancellation block 3
45,423 options at $8.55 exercise price
Cancelled for cash upon consummation of the Merger
Dispositions reported
9 transactions
Form 4 shows 9 disposition events, all coded "D"
Net direction
Dispose
transactionSummary shows disposeCount of 9 and neutral net buy/sell
Key Terms
restricted stock units, stock options ("Option"), Disposition to issuer, Merger, +1 more
5 terms
restricted stock units financial
"which included 38,205 shares of Common Stock and 75,736 restricted stock units (which vested in full..."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock options ("Option") financial
"each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment..."
Disposition to issuer regulatory
"transaction_code_description": "Disposition to issuer""
Merger financial
"disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger")"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
exercise price financial
"equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Lynn Dorsey Bleil report for Amicus Therapeutics (FOLD)?
Lynn Dorsey Bleil reported disposing of 113,941 shares of Amicus Therapeutics Common Stock at $14.50 per share. The disposition occurred in connection with the consummation of the acquisition of Amicus by BioMarin Pharmaceutical Inc., leaving no reported shares held in this filing.
How were Amicus Therapeutics stock options treated in the BioMarin merger?
Each reported Amicus stock option was cancelled and converted into a cash payment at closing. The payment equaled $14.50 per share minus the option’s exercise price, multiplied by the total number of shares subject to that option, as described in the filing footnotes.
Were Lynn Dorsey Bleil’s Amicus stock options vested at the time of the merger?
The filing footnotes state that each option was fully vested and that each option vested in full in connection with consummation of the merger. Together, these statements indicate the options were not subject to further vesting conditions when they were cancelled for cash.
What happened to Lynn Dorsey Bleil’s Amicus Common Stock in the BioMarin acquisition?
Her reported Amicus Common Stock, totaling 113,941 shares, was disposed of at $14.50 per share as part of the merger consideration. This included 38,205 shares of Common Stock and 75,736 restricted stock units that vested in full when the merger was consummated.
Did Lynn Dorsey Bleil retain any Amicus Therapeutics stock options after the merger?
According to the filing, each reported stock option was cancelled in connection with the consummation of the merger. The total stock options reported following the transactions is shown as zero, reflecting that no reported options remained outstanding in this Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.
